1998
DOI: 10.1016/s0090-3019(98)00012-3
|View full text |Cite
|
Sign up to set email alerts
|

Epidural spinal cord stimulation for treatment of chronic pain—some predictors of success. A 15-year experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
208
0
7

Year Published

2008
2008
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 291 publications
(223 citation statements)
references
References 41 publications
8
208
0
7
Order By: Relevance
“…Epidural spinal cord stimulation has long been used to treat intractable pain in patients (29,111,116,145,146,149,177,183,188,227,230). Sayenko et al (220) showed that lumbosacral epidural stimulation activated widespread rostral and caudal areas of the lumbar spinal cord, involving afferent and efferent pathways, in a patient with chronic SCI.…”
Section: Epidural Spinal Cord Stimulationmentioning
confidence: 99%
“…Epidural spinal cord stimulation has long been used to treat intractable pain in patients (29,111,116,145,146,149,177,183,188,227,230). Sayenko et al (220) showed that lumbosacral epidural stimulation activated widespread rostral and caudal areas of the lumbar spinal cord, involving afferent and efferent pathways, in a patient with chronic SCI.…”
Section: Epidural Spinal Cord Stimulationmentioning
confidence: 99%
“…The positioning of the spinal electrode should be precise in order to allow for overlap of the pain area during trial stimulation. This fact has been shown to be important for long-term efficacy of spinal cord stimulation (SCS) 24,25 . The SCS appears to be most effective in patients with impartial and postcordotomy pain 5 .…”
Section: Therapeutic Optionsmentioning
confidence: 99%
“…Cerebrospinal Stimulation and Low-dose Ketamine Drip Infusion Therapy for the Treatment of Neuropathic Pain Takamitsu YAMAMOTO 1) , Koichiro SUMI 2) , Toshiki OBUCHI 2) , Minoru OTAKA 2) , Toshikazu KANO 2) , Kazutaka KOBAYASHI 2) , Hideki OSHIMA 3) , Chikashi FUKAYA 1) and Yoichi KATAYAMA Table 1 ketamine-resistant ketamine-resistant 20% ketamine-sensitive 5.4% ketaminesensitive 9) ketamine-sensitive 100 ml 20 mg ® (0.33 mg/Kg) 1 2 (Ludiomil®) 10 30 mg/day (Lexotan®) 2 6 mg/day (GABAPEN®) 600 2400 mg/day 10,11) morphine-sensitive MS ® 30 mg/day ( ketamine-sensitive II.…”
Section: )mentioning
confidence: 99%